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Abstract
Background This study aimed to demonstrate the noninferior
efficacy of TachoSil vs. TachoComb in Japanese patients un-
dergoing liver resection and to assess the safety of TachoSil
vs. TachoComb in these patients.
Methods This randomized, double-blind, noninferiority study
(JapicCTI-090684) involved participants scheduled for liver
resection/living donors (age ≥ 20 years). TachoSil or
TachoComb (1:1 allocation ratio) was applied to control per-
sistent exudative bleeding after primary hemostasis during
liver resection/removal for donation. The primary outcome
was hemostasis 5 min after study treatment application. The
95% confidence interval (CI) for the difference in the propor-
tion of participants with hemostasis 5 min after application of
TachoSil/TachoComb was determined; noninferiority of
TachoSil was indicated if the lower limit of the CI
was ≥−14%. Adverse events (AEs) were recorded.
Results All participants in the efficacy analysis (TachoSil:
54/54, 100%; TachoComb: 54/54, 100%) achieved hemo-
stasis 5 min after study treatment application. Therefore,
TachoSil was noninferior to TachoComb. All participants
experienced ≥1 AE; however, none discontinued because
of an AE. Most (≥97.8%) AEs were mild or moderate
in severity.
Conclusions These findings confirm the safety profile and
noninferior hemostatic efficacy of TachoSil compared with
TachoComb.
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Introduction
Hemostasis during liver resection is a critical determinant of
surgical success. Indeed, the volume of blood loss during liver
surgery is an established predictor of morbidity and mortality
[1–3]. Of note, the management of hemorrhage during liver
resection can be particularly challenging compared with other
types of surgery because the hepatosinusoidal structure lacks
smooth muscle and thus the capacity to vasoconstrict [4]. As a
consequence, a variety of different approaches may be used to
manage bleeding during liver resection. Major bleeding
(strong and/or pulsating) from identifiable vessels is initially
managed by primary surgical methods (i.e., sutures, stapling
ligatures, argon beam coagulation, and electrocautery) and
then secondary hemostatic agents as necessary [5, 6].
Diffuse bleeding may be managed by argon beam coagula-
tion, electrocautery, and/or hemostatic agents, including
collagen-based sealants, synthetic glues, and fibrin sealants
[5–8]. Of these hemostatic agents, fibrin sealants have been
increasingly used for hemostasis during liver resection [9], in
which they may be used to control persistent bleeding (after
primary surgical management) and/or diffuse bleeding.
TachoComb® and TachoSil® are widely used fibrin seal-
ants for tissue adhesion/closure during different types of sur-
gery, including liver, lung, cardiovascular, gynecological, and
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urological. TachoComb comprises a collagen patch coatedwith
human fibrinogen and bovine thrombin and aprotinin. This
product version has been marketed and widely used in Japan
since 1999. The newer product version, TachoSil, is currently
marketed in more than 50 countries worldwide, and it com-
prises a collagen patch coated with human fibrinogen and hu-
man thrombin. TachoSil was developed after TachoComb to
avoid potential immunogenic effects of bovine thrombin [10]
and anaphylaxis caused by bovine aprotinin with repeated use
[11, 12], and to negate the theoretical risk of horizontal disease
transfer (bovine to human), e.g., by prions causing variant
Creutzfeldt–Jakob disease. Preclinical testing in pigs demon-
strated that there was no difference between TachoSil and
TachoComb in primary hemostasis and that aprotinin was not
required for effective hemostasis [13]. Subsequent clinical stud-
ies [14–16] carried out in Europe demonstrated that TachoSil
provides effective hemostasis during liver resection and has an
acceptable safety and tolerability profile. To date, however, no
comparison of the efficacy and safety of the two product ver-
sions has been published to demonstrate if the exclusion of
aprotinin has an impact on clinical outcomes. Likewise, the
hemostatic efficacy of TachoSil has not previously been inves-
tigated in Asians (including Japanese) with their different co-
agulation profile compared with Caucasians [17].
Accordingly, the aims of this study were to demonstrate
noninferiority in efficacy of TachoSil compared with
TachoComb in Japanese patients undergoing liver resection




This was a multicenter, randomized, double-blind, noninferior-
ity (TachoSil vs. TachoComb) study carried out at 11 sites in
Japan from 18th April 2008 to 19th August 2009. The trial was
registered in the Japan Pharmaceutical Information Center
Clinical Trial Information database (JapicCTI-090684).
The study protocol was reviewed and approved by the
Institutional Review Board at each study site. The study was
carried out in accordance with Good Clinical Practice (GCP),
based on the ethical principles outlined in the Declaration of
Helsinki and the International Conference on Harmonization-
GCP Guideline, and all applicable local Japanese laws and
regulations. All participants provided written informed consent.
Study population
Patients scheduled for elective liver resection (at least
segmental, anatomical, or non-anatomical) and living donors
were considered for inclusion in the study if they were
aged ≥20 years at the time of informed consent.
Patients and living donors were excluded from the study if
they had a Child–Pugh Classification of C; had a history of
hypersensitivity to any of the ingredients of the investigational
products, or to bovine blood-derived, bovine lung-derived, or
equine blood-derived preparations; had a history of
TachoComb use; were females who were pregnant, lactating,
suspected of being pregnant, or who planned to become preg-
nant during the study period; had participated in any other
clinical study within 180 days before providing informed con-
sent; or were judged by the investigator as not suitable to
participate in the study.
Randomization and treatment protocol
Prior to surgery, participants were randomly allocated (1:1 ratio)
to TachoSil or TachoComb using a central allocation system.
Randomization was stratified by study site, Child–Pugh classi-
fication (A or B), and platelet count (<100,000 or ≥100,000/μL).
Intra-operatively, patients with severe surgical complications
and patients with persistent bleeding after completion of the
primary hemostatic procedures were excluded from the study.
TachoSil and TachoComb were provided (Nycomed,
Zurich, Switzerland [now part of Takeda Pharmaceutical
Company Ltd]) in the form of identical 9.5 × 4.8 cm equine
collagen patches of a 0.5 cm thick spongy material with a dry
yellow coating of active ingredients on one side. Active ingre-
dients in the TachoSil patches were human fibrinogen
(5.5 mg/cm2) and human thrombin (1.38 IU/cm2). Active in-
gredients in the TachoComb patches were human fibrinogen
(5.5 mg/cm2), bovine thrombin (1.38 IU/cm2), and bovine
aprotinin (128 IU/cm2). The two study treatments were indis-
tinguishable in their appearance and physical characteristics.
Study treatment was applied at the discretion of the
investigator/subinvestigator to control persistent bleeding af-
ter primary hemostasis during liver resection or liver removal
for donation. Before application, the wound site was cleansed
of blood and body fluid. The patch was cut to the required
dimensions and applied in dry form, or moistened with phys-
iological saline just before application. The active side was
applied to the bleeding wound site and held against the site
with gentle pressure for 5 min.
To prevent potential confounding of the efficacy and safety
evaluations, participants were prohibited from taking the fol-
lowing concomitant medications from 2 days before study
treatment until day 28 after study treatment: tissue sealants
containing fibrinogen, collagen preparations, oxidized cellu-
lose preparations, local hemostatic agents, whole blood and
platelet preparations, fresh frozen plasma, procoagulants,
antifibrinolytic agents, aprotinin preparations, and other inves-
tigational drugs or medical devices.
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Outcome measures
The primary efficacy outcome was hemostasis 5 min after the
application of study treatment, which was assessed at the site
where study treatment was first applied. Blood flow occlusion
was temporarily released, if clamping was used, and the site
was visually inspected by the investigator/subinvestigator.
Hemostasis was defined as being achieved when other hemo-
static treatment was not required. If hemostasis was not ob-
tained 5 min after application, other (nonstudy) treatments
were used to control bleeding from the wound.
Adverse events (AEs) were recorded from the time of in-
formed consent until day 28 after treatment and were defined
as any unfavorable medical occurrence or worsening of sub-
jective symptoms/objective findings, worsening of underlying
diseases and complications, or clinically significant abnormal
laboratory values. Adverse events were coded according to
MedDRA, version 11.0.
Serological tests for hepatitis B and C virus (HBV and
HCV) and human immunodeficiency virus (HIV) were per-
formed the day before study treatment and at day 28.
Statistical analysis
Based on the results from European clinical studies of patients
undergoing liver resection, 95% of Japanese participants were
expected to achieve hemostasis at 5 min. A sample size of 100
participants (50 per study group) was determined to provide
90% power at a noninferiority margin of 0.14.
The efficacy analysis population for demonstrating non-
inferiority was the per protocol set and included all enrolled
participants who received the allocated study treatment and
from whom any data was collected (full analysis set), in
accordance with the intention-to-treat principle [18]. The safe-
ty analysis population included all enrolled participants who
received the allocated study treatment and provided any data.
The primary efficacy analysis, designed to demonstrate
noninferiority of TachoSil compared with TachoComb, was
the 95% confidence interval (CI) for the difference between
TachoSil and TachoComb in the proportion of participants
with hemostasis 5 min after application of TachoSil or
TachoComb. Noninferiority of TachoSil was considered to
be demonstrated if the lower limit of the 95% CI was greater
than −14%. The 95%CI for the proportion of participants with
hemostasis at 5 min in each group was also calculated using
the score method by Wilson [19]. The difference in the pro-
portion of participants with hemostasis at 5 min between the
TachoSil and TachoComb groups was compared using
Fisher’s exact test.
Safety analysis comprised the number of AEs, the number
of participants who experienced AEs, and the number of par-
ticipants who were HBV, HCV, and HIV positive at day 28.
Results
Disposition of participants
A total of 130 participants were randomized to treatment, 64
to TachoSil and 66 to TachoComb (Fig. 1). Of the 64 partic-
ipants randomized to TachoSil, 55 (85.9%) received study
treatment, two (3.1%) discontinued from study participation,
and 53 (82.8%) completed the study. Of the 66 participants
randomized to TachoComb, 56 (84.8%) received study treat-
ment, two (3.0%) discontinued from study participation, and
53 (80.3%) completed the study (note: one participant in this
group completed the study, but did not complete the day 28
examination). Except for one participant in the TachoSil group
who died due to intra-abdominal hemorrhage, all other
participants who were discontinued had prohibited con-
comitant medications.
The efficacy analysis population included 54 participants
in both study groups. The safety analysis population included
55 participants in the TachoSil group and 56 participants in the
TachoComb group.
Demographic, baseline, and surgical characteristics
Demographic and baseline characteristics were generally sim-
ilar between study groups (Table 1), although there were more
alcohol users (37.0 vs. 14.8%) and fewer patients undergoing
surgery due to liver donation (22.1 vs. 3.7%) in the TachoSil
group compared to the TachoComb treatment group. Overall,
surgical characteristics were balanced between TachoSil and
TachoComb treatment groups, respectively, with small differ-
ences in the use of drip bipolar (14.8 vs. 20.8%) and clamp
crushing technique (13.0 vs. 7.4%) for hepatic resection
(Table 2). Likewise, there were differences in the propor-
tion of patients receiving intraoperative blood transfusion.
More participants had a history of chemotherapy for
hepatic disease in the TachoSil group compared with the
TachoComb group.
Primary outcome measure
All participants in the efficacy analysis population in both
study groups (TachoSil: 54/54, 100%; TachoComb: 54/54,
100%) achieved hemostasis 5 min after the application of
study treatment. There was no difference in the response rate
between study groups (p = 1.0). The 95% CI for the propor-
tion of participants who achieved hemostasis at 5 min was
93.4 to 100% for both groups. The 95% CI for the difference
in the proportion of participants who achieved hemostasis at
5 min between study groups was −4.9 to 4.9%, indicating that
TachoSil was noninferior to TachoComb.
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Safety
The proportion of participants who experienced AEs was gen-
erally similar between study groups (Table 3). All participants
in both study groups experienced at least one AE; however, no
participants discontinued because of an AE. Most (≥97.8%)
AEs in both groups were classified as mild or moderate in
severity. The incidence of possibly treatment-related AEs was
greater in the TachoSil group than in the TachoComb group.
A small number of participants experienced at least one
serious AE (SAE), most of which were not considered to be
related to study treatment. In the TachoSil group, seven
participants experienced a total of eight SAEs, including
ventricular flutter, peritonitis, intra-abdominal hemorrhage,
pyrexia, post-procedural bile leak, atelectasis, aneurysm rup-
tured, and vascular pseudoaneurysm (all n = 1). The SAEs of
post-procedural bile leak and peritonitis were considered to be
possibly treatment related. The participant who experienced
intra-abdominal hemorrhage died; this SAE was not consid-
ered to be related to study treatment because the event was a
rupture caused by hepatic artery aneurysm resulting from the
surgery. In the TachoComb group, nine participants experi-
enced a total of 10 SAEs, including post-procedural bile leak
(n = 4), and ventricular fibrillation, gastritis, abdominal ab-
scess, upper limb fracture, chylothorax, and arterial hemor-
rhage (all n = 1). The SAE of ventricular fibrillation was
considered to be possibly treatment related. One participant
in the TachoComb group died after the study period due to
worsening of underlying disease; this death was not consid-
ered to be related to study treatment.
The incidence of AEs (by preferred term) was generally
similar between study groups (Table 4), with wound
Fig. 1 Disposition of
participants. One participant did
not discontinue treatment, but did





Characteristic TachoSil N = 54 TachoComb N = 54
Males, n (%) 37 (68.5) 35 (64.8)
Age (years), mean ± SD 59.9 ± 12.2 65.5 ± 11.3
BMI (kg/m2), mean ± SD 23.7 ± 3.2 22.6 ± 2.8
Smokers, n (%) 20 (37.0) 8 (14.8)
Alcohol use, n (%) 23 (42.6) 20 (37.0)
Reason for surgery, n (%)
Hepatic disease 48 (88.9) 52 (96.3)
Liver donor 6 (11.1) 2 (3.7)
Child–Pugh classification, n (%)
A 53 (98.1) 52 (96.3)
B 1 (1.9) 2 (3.7)
Platelets (×104/μL), mean ± SD 20.7 ± 9.1 19.0 ± 6.7
Previous chemotherapy for hepatic disease, n (%) 19 (35.2) 8 (14.8)
BMI body mass index, SD standard deviation
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complication (defined as pruritus of the wound and periwound
skin, wound pain, wound site pain, or wound pain in the but-
tocks) and pyrexia being the most commonly reported AEs,
experienced by ≥73.2% of participants in both study groups.
Changes in laboratory values were similar between groups
(data not shown). One participant in the TachoSil group experi-
enced a clinically significant, but nonserious, abnormal laborato-
ry value of C-reactive protein increase that was considered related
to study treatment. There were no new cases of HBV, HBC, or
HIV infection, nor were there any positive conversions for par-
ticipants who had positive virus markers at the start of the study.
Discussion
This is the first randomized trial to compare the efficacy and
safety of TachoSil and TachoComb in Japanese patients un-
dergoing liver resection or living donors. We found that
Table 2 Participants’ surgical
characteristics Characteristic TachoSil N = 54 TachoComb N = 54
Method of liver resection, n (%)
CUSA 44 (81.5) 42 (77.8)
Drip bipolar 8 (14.8) 11 (20.4)
Harmonic scalpel 9 (16.7) 9 (16.7)
Clamp crush 7 (13.0) 4 (7.4)
Bipolar scissors 4 (7.4) 5 (9.3)
Other 20 (37.0) 15 (27.8)
Number of resection sites, mean ± SD 2.6 ± 1.40 3.1 ± 1.5
Weight of liver resected (g), mean ± SD 315.3 ± 274.2 338.4 ± 302.1
Intraoperative blood transfusion, n (%)
Before efficacy evaluation 0 (0) 3 (5.6)
After efficacy evaluation 12 (22.2) 8 (14.8)
Blood flow occlusion, n (%) 47 (87.0) 49 (90.7)
Method of primary hemostasis, n (%)
Suture 18 (33.3) 18 (33.3)
Ligation 13 (24.1) 17 (31.5)
Electrocoagulation 43 (79.6) 45 (83.3)
Compression 23 (42.6) 19 (35.2)
Volume of bleeding (mL), mean ± SD 649.5 ± 932.2 666.3 ± 499.0
Size of patch used, n (%)
9.5 × 4.8 cm 9 (16.7) 11 (20.4)
4.8 × 4.8 cm 5 (9.3) 1 (1.9)
2.4 × 4.8 cm 6 (11.1) 4 (7.4)
2.4 × 2.4 cm 21 (38.9) 27 (50.0)
Other 13 (24.1) 11 (20.4)
CUSA Cavitron ultrasonic surgical aspirator, SD standard deviation
Table 3 Summary of
adverse events Adverse event TachoSil N = 55 TachoComb N = 56
One or more AE, n (%) 55 (100.0) 56 (100.0)
One or more possibly treatment-related AE, n (%) 10 (18.2) 1 (1.8)
Discontinuation because of an AE, n (%) 0 (0) 0 (0)
One or more SAE, n (%) 7 (12.7) 9 (16.1)
Total AEs, n 329 303
Mild, n (%) 263 (79.9) 232 (76.6)
Moderate, n (%) 59 (17.9) 65 (21.5)
Severe, n (%) 7 (2.1) 6 (2.0)
AE adverse event, SAE serious adverse event
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TachoSil has noninferior hemostatic efficacy compared with
TachoComb and appears to have a similar safety profile. Our
findings therefore suggest that the beneficial effects of
TachoSil are similar to those of TachoComb and that
TachoSil is an effective means of providing hemostasis in
Japanese patients during surgery.
The primary finding of our study was that TachoSil and
TachoComb provided similarly effective hemostasis within
5 min of application in all participants. The assessment of
hemostasis was judged by the surgeon; however, the binary
nature of the endpoint avoids any grading and thus renders
some objectivity. This endpoint reflects the immediate phar-
macodynamic effect of the products, and although of minor
clinical relevance, this kind of efficacy endpoint is widely
used and acknowledged as basis for the assessment of hemo-
static effect of treatments in surgery [4, 15, 20–22]. To our
knowledge, no other published clinical study has directly
compared the hemostatic efficacy of TachoSil and
TachoComb. However, our findings are supported by those
from nonclinical studies. [23] Notably, Agger et al. [13] found
that TachoSil and TachoComb had similar hemostatic efficacy
in a pig model of challenging aortic arterial bleeding. The
findings from the current study support other published data
showing that TachoSil is an effective means of providing he-
mostasis during liver resection. Specifically, two European,
multicenter, randomized, controlled trials, involving 121
[16] and 119 [14] adults, respectively, demonstrated that
TachoSil provided superior or significantly faster hemostasis
compared with argon beamer during liver resection. Likewise,
a US, multicenter, randomized, controlled trial, involving 224
adults, demonstrated that TachoSil provided superior hemo-
stasis to Surgicel® during liver resection [20]. A small pro-
spective study [15] involving 16 children undergoing liver
resection also demonstrated that 81.3% of participants had
effective hemostasis within 3 min of application of TachoSil.
Further, TachoSil has also been reported to provide effective
hemostasis during various other types of surgery, including
lung surgery [24, 25], kidney tumor resection [22], prostate
surgery [26], gynecological surgery [27–29], and cardiovas-
cular surgery in patients requiring cardiopulmonary bypass
[21]. The current published literature on use of TachoSil in
Japan is restricted to a recently published retrospective study
[30], a case report [31], and a case series [32]. In the retro-
spective study, which involved 75 patients, the application of
TachoSil or TachoComb to the staple line of the pancreas after
distal pancreatectomy was associated with a low rate of fistula
Table 4 Adverse events
occurring at a rate of >5% Adverse event (preferred term), n (%) TachoSil N = 55 TachoComb N = 56
Wound complicationa 51 (92.7) 47 (83.9)
Pyrexia 44 (80.0) 41 (73.2)
Insomnia 17 (30.9) 12 (21.4)
Vomiting 11 (20.0) 8 (14.3)
Nausea 10 (18.2) 10 (17.9)
Abdominal distension 9 (16.4) 6 (10.7)
Musculoskeletal pain 9 (16.4) 5 (8.9)
Pleural effusion 8 (14.5) 14 (25.0)
Constipation 8 (14.5) 9 (16.1)
Ascites 6 (10.9) 5 (8.9)
Diarrhea 5 (9.1) 8 (14.3)
Hyperglycemia 5 (9.1) 5 (8.9)
Atelectasis 5 (9.1) 5 (8.9)
Pain 4 (7.3) 2 (3.6)
Blood pressure increased 4 (7.3) 1 (1.8)
Post-procedural bile leak 3 (5.5) 8 (14.3)
Back pain 3 (5.5) 4 (7.1)
Pruritus 3 (5.5) 3 (5.4)
Urine output decreased 3 (5.5) 2 (3.6)
Erythema 3 (5.5) 2 (3.6)
Rash 3 (5.5) 2 (3.6)
Cholangitis 2 (3.6) 5 (8.9)
Delirium 1 (1.8) 7 (12.5)
Abdominal abscess 0 (0) 3 (5.4)
a Pruritus of the wound and periwound skin, wound pain, wound site pain, or wound pain in the buttocks
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formation [30]. The case report [31] and case series [32] de-
scribe successful pulmonary and renal application, respectively.
TachoSil was developed to reduce the potential for immu-
nogenic effects in response to bovine thrombin and bovine
aprotinin with repeated use, and to remove the potential for
horizontal disease transfer (bovine to human). While no spe-
cific antibody testing was undertaken in the current analyses, a
recent study reported that among 97 patients using TachoSil
for the secondary treatment of local bleeding after hepatic
resection, immunogenicity findings did not appear to be clin-
ically significant [20]. No treatment emergent AEs related to
immune response were reported in the initial 6-month follow-
up period, and no medical conditions potentially related to
antibody development were observed in an extended follow-
up of up to 2 years.
We did not aim to assess the long-term safety of TachoSil in
this study; however, the safety profile of TachoSil in clinical
practice has been confirmed in postmarketing settings [33],
through an estimated 5.2 million patient exposures worldwide
(data on file). The findings from randomized controlled trials
of TachoSil carried out in Europe, involving participants un-
dergoing liver resection [14, 16] and other types of surgery
[21, 22, 24], have also confirmed the favorable safety profile
of TachoSil. Our study findings indicate that the safety pro-
files of TachoSil and TachoComb are similar for up to 28 days
following use for hemostasis in Japanese patients undergoing
liver resection or living donors. Treatment-related AEs were
more common in the TachoSil group than in the TachoComb
group. This difference likely relates to a random imbalance in
treatment assignment to two investigators, both of whom prac-
ticed standards for the evaluation of the definition of Bcausal
relationship^ differently from the other investigators. All other
aspects of safety including total AEs and patients with one or
more SAEs were similar in the two treatment groups. Most
AEs were of mild or moderate severity and few SAEs were
reported. The incidence of AEs in our study is also higher than
the incidence of AEs in the European studies of patients un-
dergoing liver resection (100% of participants vs. 42 to 44%
of participants [14, 16]). We suggest that this disparity likely
reflects methodological differences in the prespecified criteria
for recording or not recording specific AEs or the cautious
practice of Japanese investigators. In particular, AEs that are
common after liver resection, such as wound complication,
nausea, vomiting, and pain, were recorded in our study, but
not in the European studies.
A key strength of this study is the prospective, randomized,
double-blind, multicenter design with predefined statistical
analyses based on the intention-to-treat paradigm. Limitations
include the length of follow-up, which may have been insuffi-
cient to detect longer term postoperative morbidities, and the
moderate number of participants. Additionally, one of the
authors (M. Kobayashi) was sponsor-affiliated, which incurs
a risk of bias [34]. However, the primary contributors to the
study design and the scientific interpretation of the data were
the authors affiliated with academic research institutions.
Conclusion
This study demonstrated that TachoSil has noninferior hemo-
static efficacy compared with TachoComb, and a similar
safety profile, in patients undergoing liver resection.
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